New Zealand Pharmaceuticals and Healthcare Report Q4 2011 Now Available at MarketPublishers.com

30 Aug 2011 • by Natalie Aster
New Zealand Pharmaceuticals and Healthcare Report Q4 2011 Now Available at MarketPublishers.com

LONDON – New Zealand ranks 56.3 out of 100 in the Q411 Pharmaceutical Business Environment Ratings and has the ninth most attractive pharmaceutical industries in Asia Pacific, behind Malaysia and ahead of India. New Zealand’s pharmaceutical market has traditionally low risk environment. International drugmakers are allured to the country’s market thanks to non-communicable disease expansion, developed system advertising of prescription drugs, an ageing population and the healthy political system. In June 2011, for example, US-based multinational company Pfizer launched production of a generic version of its erectile dysfunction medication Viagra in New Zealand. This drug is called Avigra, and is expected to be sold at around half the price of Viagra, making it more affordable for New Zealand consumers.

New market research report New Zealand Pharmaceuticals and Healthcare Report Q4 2011prepared by Business Monitor International offers complete review of New Zealand pharmaceuticals and healthcare sector highlighting its development and performance in the fourth quarter of 2011.  The study delves into an insightful discussion of the segment and overall country SWOT, competitive landscape and top competitors profiles, growth factors and challenges analysis.

Report Details:

Title: New Zealand Pharmaceuticals and Healthcare Report Q4 2011
Published: August, 2011
Pages: 43
Price: US$ 530

Report Contents:

Executive Summary
SWOT Analysis
New Zealand Pharmaceuticals & Healthcare Industry SWOT
New Zealand Political SWOT
New Zealand Economic SWOT
New Zealand Business Environment SWOT
Business Environment Ratings
Pharmaceuticals Business Environment Ratings
Table: Asia Pacific – Regional Pharmaceutical Business Environment Ratings, Q411
Rewards
Risks
New Zealand – Market Summary
Regulatory Regime
Intellectual Property Protection
Pricing And Reimbursement
Table: Leading Therapeutic Groups By PHARMAC Expenditure (NZDmn)
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
Recent Regulatory Developments
Industry Developments
Epidemiology
Clinical Trials Sector
Industry Forecast Scenario
Pharmaceutical Market Forecast
Table: New Zealand’s Pharmaceutical Market Forecast, 2008-2015
Key Growth Factors – Industry
Table: New Zealand’s Healthcare Expenditure Forecast, 2008-2015
Key Growth Factors – Macroeconomic Forecast
Table: New Zealand – Economic Activity, 2008-2015
Key Risks To BMI’s Forecast Scenario
Key Risks To BMI’s Forecast Scenario
Competitive Landscape

To order the report or ask for free sample pages, please contact ps@marketpublishers.com

 

CONTACTS

The Market Publishers, Ltd.

Tanya Rezler

Tel: +44 208 144 6009

Fax: +44 207 900 3970

ps@marketpublishers.com

www.marketpublishers.com